Park et al. [157]
|
105 49/56
|
24.1/53.7
|
3.4/6.5 p < 0.001
|
NR
|
NR
|
NR
|
NR
|
NR
|
21/3
|
DeMaria et al. [167]
|
39 21/18
|
12–24
|
0.8/4.4 p < 0.05
|
NR
|
Initial and readmission cost 8,273 ± 2,950/12,461 ± 5,987 p < 0.05
|
NR
|
Analgesic use 10 versus 79 % p < 0.05
|
NR
|
5/0
|
McKinlay et al. [208]
|
170 69 Recurrent 101 Primary
|
19/27
|
NR
|
NR
|
NR
|
NR
|
NR
|
2.8 %/0 % in recurrent versus primary
|
7 Recur-rent 5 Primary p = 0.53
|
Lomanto et al. [113]
|
100 50/50
|
20.8
|
2.7/4.7 p = 0.044
|
NR
|
NR
|
NR
|
VAS 2.9/4.1 p = 0.001
|
NR
|
2/10
|
Olmi et al. [154]
|
50 25/25
|
9/24.5
|
NR
|
NR
|
NR
|
NR
|
NR
|
NR
|
2/0
|
Bingener et al. [73]
|
360 127/233
|
36/25
|
0.9 ± 1.4/1.4 ± 2.0 p = 0.01
|
NR
|
NR
|
NR
|
NR
|
NR
|
9/12 p = 0.36
|
Ching et al. [211]
|
168 all lap 42 mor-bidly obese/124 nonobese
|
19
|
NR
|
NR
|
NR
|
NR
|
NR
|
Obese/nonobese 5 %/10 % p = 0.5
|
Obese/nonobese 10/13 p = 0.78
|
Ceccarelli et al. [212]
|
181 94/87
|
38
|
NR
|
NR
|
NR
|
NR
|
NR
|
NR
|
2.1/6.9 p > 0.05
|
Kurmann et al. [87]
|
125 69/56
|
32.5/65
|
6 (1–23)/7 (1–67) p = 0.001
|
21/42 p > 0.05
|
NR
|
NR
|
NR
|
VAS 0.5/0.6 p > 0.05
|
18/16 p = 0.6
|
Total
|
960 435/525
|
24.8/34.4 (7 studies)
|
2.7/4.6 (5 studies)
|
21/42 (1 study)
|
8,273 ± 2,950/12,461 ± 5,987 (1 study)
|
NR
|
2.9/4.1p = 0.001 (1 study)
|
0.5/0.6 p > 0.05 (1 study)
|
8.4/6.8 (7 studies)
|